ViiV Healthcare, the HIV-focused company majority owned by GSK (NYSE: GSK), presented multiple studies at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro covering its long-acting injectable HIV treatment and prevention medicines.

Week 96 results from the LATA trial, led by University College London, showed cabotegravir plus rilpivirine (Cabenuva), dosed every two months, was superior to daily oral dolutegravir/tenofovir disoproxil fumarate/lamivudine in 476 virologically suppressed adolescents aged 12 to 19 living with HIV across Kenya, South Africa, Uganda and Zimbabwe. Confirmed viral rebound occurred in 0.9% of adolescents receiving Cabenuva versus 6.4% receiving daily oral therapy. Among participants, 94% reported long-acting injections were much easier to take than daily oral treatment.

Separately, real-world data from the US-based OPERA cohort showed Cabenuva maintained virologic suppression comparable to daily oral bictegravir/emtricitabine/tenofovir alafenamide in nearly 6,800 adults, with 89% of Cabenuva recipients achieving viral load below 50 copies/mL at a median follow-up of 15 months.

The phase I CLARITY study, comparing injection experience between long-acting cabotegravir (Apretude) and lenacapavir in 63 participants without HIV, found that 70% rated the cabotegravir injection as "very acceptable" or "totally acceptable" at six months, versus 37% for lenacapavir. Ninety percent of lenacapavir participants continued to report nodules at six months, compared with 20% for cabotegravir.

The CAPTIVATE study, covering 241 PrEP users across 18 US sites, found that 97% of participants with prior oral PrEP experience preferred long-acting cabotegravir for PrEP. The PrEPFACTS real-world analysis of 2,913 US users found overall adherence was high, with 89% covered by PrEP for at least 90% of the measured period.

ViiV Healthcare also presented baseline data from the phase IIb EXTEND 4M study, which is evaluating an investigational intramuscular cabotegravir formulation dosed three times a year for HIV prevention, with 229 participants enrolled across 27 US sites. Full study results are expected at a future medical congress.